Oncology Pharmacogenomics
What Is Oncology Pharmacogenomics?
Oncology pharmacogenomics examines how a person’s inherited genetic variations may influence their response to certain cancer medicines, including how the body processes these drugs and the risk of specific side effects. The findings can help clinicians make informed treatment decisions, including dose adjustments where supported by clinical guidelines. Learn more about pharmacogenomics and its role in personalised medicine.
For example, variations in the DPYD gene can increase the risk of severe toxicity from fluoropyrimidine medicines such as fluorouracil (5-FU) and capecitabine. Testing for relevant variants before treatment may help clinicians assess this risk.
Pharmacogenomics vs Tumour Genomic Testing
- Oncology pharmacogenomics: Examines the patient’s genetic variations that may affect how certain medicines are processed or tolerated.
- Tumour genomic testing: Examines genetic changes in cancer cells that may help guide targeted treatment decisions.
Pharmacogenomic testing does not predict every treatment response or guarantee that side effects will be avoided. Results should be interpreted alongside clinical history, the planned treatment and relevant medical guidelines.
How Can Inherited Genetic Variants Affect Cancer Drug Response?
Inherited genetic variants can influence how the body processes certain cancer medicines, potentially affecting drug exposure, treatment response and the risk of side effects. Their impact depends on the specific gene and medicine involved. These relationships are assessed within pharmacogenomics, which can help inform prescribing decisions when supported by clinical evidence.
Key Ways Genetic Variants Can Influence Treatment
- Drug metabolism: Some variants reduce the activity of enzymes that break down medicines, potentially increasing drug exposure and toxicity.
- Drug activation: Certain medicines require activation in the body. Genetic differences may affect how efficiently this occurs.
- Drug inactivation: Variants can alter how quickly a medicine or its active metabolites are inactivated or cleared.
- Risk of adverse effects: Reduced enzyme activity can increase the risk of serious toxicity from particular cancer medicines, even at standard doses.
For example, reduced activity of the DPYD enzyme can impair the breakdown of fluorouracil and capecitabine, increasing the risk of severe toxicity. Identifying relevant variants may help clinicians determine whether dose adjustments or alternative treatments should be considered. Where a dose adjustment is appropriate, personalised drug dosing based on genetics may help inform the decision in line with clinical guidance.
These effects relate to the patient’s inherited genetic makeup, rather than genetic changes within the tumour. Results must be interpreted alongside other factors, including organ function, other medicines and the relevant clinical guidelines.
Which Gene–Drug Interactions Matter in Oncology Pharmacogenomics?
Some inherited genetic variants can affect how cancer medicines are processed, increasing the risk of serious side effects. The following gene–drug pairs have established clinical relevance in specific treatment settings, although testing recommendations depend on the medicine, clinical guidance and individual circumstances.
| Gene | Associated Medicines | Potential Clinical Impact | How Results May Inform Treatment |
|---|---|---|---|
| DPYD | Fluorouracil (5-FU) and capecitabine | Reduced DPD enzyme activity can increase drug exposure and the risk of severe or potentially life-threatening toxicity. | Results may support an appropriate starting-dose adjustment or consideration of an alternative, in line with relevant clinical guidance. |
| UGT1A1 | Irinotecan | Certain variants can reduce SN-38 clearance and increase the risk of severe neutropenia and, in some circumstances, diarrhoea. | Depending on the genotype, planned regimen and applicable guidance, results may inform the initial dose or closer monitoring. |
| TPMT and NUDT15 | Thiopurines, such as mercaptopurine, in relevant oncology settings | Reduced enzyme activity can increase the risk of severe bone marrow suppression. | Results may guide dose reduction or alternative treatment strategies where recommended for the specific medicine and clinical setting. |
Clinical context matters. Pharmacogenomic results do not determine treatment on their own. Clinicians interpret them alongside the planned regimen, organ function, other medicines and relevant prescribing guidance. The genes included in a test panel may also vary.
Which Cancer Treatments May Be Affected by Pharmacogenomic Findings?
Pharmacogenomic findings are most useful when reliable evidence links a specific genetic variant to the safety or handling of a particular cancer medicine. Examples include:
- Fluoropyrimidine chemotherapy: Fluorouracil (5-FU) and capecitabine may cause severe toxicity in people with certain DPYD variants.
- Irinotecan treatment: Variants in UGT1A1 can affect drug-metabolite clearance and may influence toxicity risk and dosing decisions.
- Thiopurine medicines: In relevant cancer treatment settings, TPMT and NUDT15 variants can help inform dosing because reduced enzyme activity increases the risk of bone marrow suppression.
Does Every Patient Need Pharmacogenomic Testing?
No. The relevance of testing depends on the medicine being considered, the strength of the gene–drug evidence and applicable clinical guidance. Testing may be recommended before certain treatments or considered in specific circumstances; it is not automatically necessary for every cancer medicine or every patient.
Pharmacogenomic results are interpreted alongside the treatment plan, organ function, other medicines and clinical monitoring. They support individualised prescribing decisions but do not predict every side effect or determine whether a cancer treatment will be effective against the tumour.
Who May Benefit from Oncology Pharmacogenomics Testing?
Oncology pharmacogenomics testing may be useful for patients whose treatment involves a medicine with an established gene–drug interaction. Its relevance depends on the planned treatment, the available evidence and applicable clinical recommendations.
Who Might Consider Testing?
- Patients preparing to start specific cancer medicines: Testing may be recommended before treatments such as fluorouracil or capecitabine, where relevant DPYD variants can increase the risk of severe toxicity.
- Patients being considered for irinotecan: UGT1A1 testing may be relevant when supported by the planned regimen and applicable clinical guidance.
- Patients receiving thiopurines in relevant oncology settings: TPMT and NUDT15 results may help inform prescribing and dosing decisions.
- Patients with a history of unexpected or severe drug toxicity: Testing may be considered if the reaction could plausibly relate to a recognised genetic variation affecting the medicine involved.
- Patients whose clinical circumstances meet testing recommendations: A clinician may recommend or consider testing based on the medicine, treatment protocol and relevant professional guidance.
Not every patient with cancer needs oncology pharmacogenomic testing. The decision should be based on the medicines being considered and whether a validated gene–drug association could meaningfully inform treatment. Discussing your medical history, testing options and the implications of genetic results through genetic counselling may help you make an informed decision alongside your treating oncology team.
How Does Oncology Pharmacogenomics Testing Work?
Oncology pharmacogenomics testing follows a structured process to identify whether relevant inherited genetic variants may influence the safety or dosing of a planned cancer medicine. The appropriate test depends on the medicine, the clinical question and the available evidence.
1. Reviewing the Medicine
2. Selecting the Appropriate Test
3. Sample Collection and Analysis
4. Interpreting the Results
5. Discussing the Results with the Treatment Team
Testing is tailored to the clinical question. Sample requirements, available genes and turnaround times vary by test and laboratory. Confirm these details with the service provider before testing. Pharmacogenomic results support clinical decisions but do not replace an oncologist's assessment.
How Can Pharmacogenomic Results Inform Cancer Treatment Decisions?
Oncology pharmacogenomics results can help clinicians assess whether inherited genetic variants may affect the safety or handling of a specific cancer medicine. When supported by established clinical guidelines, these findings can inform prescribing decisions and help tailor treatment to the individual patient.
How Results May Influence Treatment
- Reviewing the starting dose: For certain gene–drug pairs, results may support a lower initial dose or another dose adjustment to reduce the risk of serious toxicity.
- Considering an alternative medicine: If a genetic finding indicates a significant risk with a particular drug, the oncology team may consider an alternative where appropriate and clinically suitable.
- Planning additional precautions: Results may help clinicians determine whether closer monitoring or specific safety measures are warranted during treatment.
- Supporting evidence-based prescribing: Recommendations should reflect the relevant gene–drug interaction, the patient’s result and recognised prescribing guidelines.
For example, a clinically significant DPYD result may inform the starting dose of fluorouracil or capecitabine, while relevant UGT1A1 findings may influence decisions about irinotecan dosing in accordance with applicable guidance.
Why Clinical Assessment Remains Essential
Pharmacogenomic results are only one part of treatment planning. The oncology team must also consider factors such as kidney and liver function, other medicines, the planned treatment regimen, the patient’s overall health and the clinical goals of treatment.
The treating oncology team makes the final decision. Pharmacogenomic testing does not independently determine the most effective cancer treatment, and dose changes or alternative medicines should only be considered following an appropriate clinical assessment.
What Are the Potential Benefits and Limitations of Oncology Pharmacogenomics?
Oncology pharmacogenomics can support safer prescribing for certain cancer medicines, but its usefulness depends on the specific gene–drug interaction, the evidence available and the scope of the test.
| Potential Benefits | Limitations |
|---|---|
|
Identifying certain toxicity risks Relevant variants, such as those in DPYD, can help identify patients at increased risk of severe toxicity from specific medicines. |
Not all risks can be predicted Many adverse effects arise from factors beyond inherited genetic variation, so testing cannot identify every patient who may experience toxicity. |
|
Supporting initial dose selection For established gene–drug interactions, results may inform starting-dose adjustments in line with clinical guidelines. |
Evidence varies by gene and medicine Not every proposed gene–drug association has sufficient evidence to guide treatment, and recommendations differ between medicines and clinical settings. |
|
Informing treatment precautions Findings may support closer monitoring or consideration of an alternative medicine when recommended by relevant guidance. |
Limited test coverage A panel may examine only selected genes or variants and may not detect every genetic change relevant to a medicine. |
|
Supporting individualised prescribing Genetic findings can add useful information to clinical assessment and other factors that influence medicine selection and dosing. |
Cannot predict anti-tumour effectiveness on its own Pharmacogenomic testing does not establish whether a cancer medicine will control a particular tumour or guarantee better treatment outcomes. |
Pharmacogenomic testing is one part of treatment planning. Its results should be interpreted alongside the patient's clinical condition, planned treatment and current prescribing guidance. Testing can inform specific decisions, but it cannot replace an oncologist's assessment or eliminate all treatment risks.
What Should You Consider Before Oncology Pharmacogenomics Testing?
Before arranging oncology pharmacogenomics testing, it is important to establish whether the results could meaningfully inform a planned cancer treatment. The following considerations can help you discuss testing with your oncology team.
- The planned medicine: Check whether the cancer medicine being considered has an established gene–drug interaction that may inform prescribing or dosing decisions.
- Timing of testing: Where testing is recommended before treatment, allow time for the result to be available and reviewed before the relevant medicine is started, where clinically appropriate.
- Test panel coverage: Confirm which genes and variants are analysed and whether the test covers those relevant to the planned medicine. A negative result does not exclude every potentially relevant genetic variant.
- Laboratory quality: Ask about the laboratory’s quality assurance, testing methods and relevant accreditation or regulatory status.
- Clinical interpretation: Results should be interpreted using reliable evidence and current prescribing guidance, with input from appropriately qualified professionals.
- Data privacy: Understand how your genetic information will be stored, accessed, shared and protected, including the applicable privacy policy and consent arrangements.
- Potential impact on treatment: Consider whether the result could influence a specific decision, such as the starting dose, additional monitoring or the choice of medicine.
It is also important to discuss the cost, expected turnaround time and practical arrangements with the testing provider. These details vary by test and laboratory and should be confirmed before proceeding.
Before making a decision, speak with your oncology team. They can help determine whether testing is appropriate for your treatment plan, whether it is recommended by relevant clinical guidance and how the findings could be used in your care.
Frequently Asked Questions About Oncology Pharmacogenomics
What Is the Difference Between Oncology Pharmacogenomics Testing and Tumour Genetic Testing?
Oncology pharmacogenomics testing examines inherited genetic variations that may affect how the body processes or responds to certain cancer medicines. Tumour genetic testing analyses genetic changes in cancer cells to help identify characteristics that may inform diagnosis or treatment selection. These tests answer different clinical questions and are not interchangeable.
Which Genes Are Commonly Examined in Oncology Pharmacogenomics Testing?
Relevant genes depend on the planned medicine and the test panel. Examples include DPYD, associated with fluorouracil and capecitabine toxicity; UGT1A1, relevant to irinotecan; and TPMT and NUDT15, which can inform thiopurine prescribing in relevant oncology settings. Not every panel includes all these genes.
When Should Oncology Pharmacogenomics Testing Be Performed?
When testing is recommended before a particular medicine is prescribed, it is generally preferable to obtain and review the result before treatment begins, where clinically appropriate. The timing should be coordinated with the oncology team to avoid unnecessary delays in cancer care.
Can Pharmacogenomic Testing Help Determine the Correct Cancer Drug Dose?
For certain established gene–drug interactions, results can inform the initial dose or support consideration of an alternative medicine, in accordance with clinical guidelines. However, dosing decisions also depend on factors such as organ function, other medicines, the treatment regimen and the patient’s overall condition.
Does Oncology Pharmacogenomics Testing Identify All Possible Side Effects?
No. Testing can identify certain inherited genetic factors associated with an increased risk of specific adverse effects, but it cannot predict every side effect. Other genetic factors, drug interactions, organ function and individual clinical circumstances can also influence treatment safety.
Can Pharmacogenomic Testing Predict Whether Cancer Treatment Will Work?
Not on its own. Pharmacogenomic testing primarily helps assess how inherited genetic variations may influence medicine handling, dosing or toxicity. It does not establish whether a medicine will effectively control a particular tumour. Treatment effectiveness depends on additional factors, including tumour biology and the patient’s clinical circumstances.
Does Every Patient with Cancer Need Pharmacogenomic Testing?
No. Testing is relevant when a medicine has a clinically meaningful gene–drug association and the result may inform a treatment decision. Whether testing is recommended depends on the specific medicine, applicable clinical guidance and individual circumstances.
What Does a Negative Pharmacogenomic Test Result Mean?
A negative result means that the test did not identify the particular variants it was designed to detect. It does not exclude every potentially relevant genetic variant or guarantee that a patient will not experience adverse effects. Interpretation depends on the test’s coverage and the clinical question.
Who Should Interpret Oncology Pharmacogenomics Results?
Results should be interpreted by appropriately qualified healthcare professionals using current clinical guidance and the patient’s treatment information. The treating oncology team is responsible for integrating the findings into decisions about medication, dosing and monitoring.
Can Pharmacogenomic Test Results Be Used for Future Cancer Treatments?
Potentially. Some inherited pharmacogenomic findings may remain relevant when considering other medicines in the future. However, their usefulness depends on the medicines involved, the scope of the original test and whether clinical recommendations have changed. Results should be reviewed in the context of each new treatment plan.
Discuss Oncology Pharmacogenomic Testing with Our Team
Considering pharmacogenomic testing as part of cancer treatment? Discuss whether testing may be relevant to your planned medicine and clinical circumstances, and how the findings could inform prescribing decisions.
Explore Whether Testing Is Appropriate for You
The value of oncology pharmacogenomic testing depends on the medicine being considered, the strength of the relevant gene–drug evidence and applicable clinical guidance. A discussion with our team can help you understand the potential role of testing, its limitations and the questions to raise with your treating oncology team.
Contact London Genetics to discuss your circumstances and explore whether oncology pharmacogenomic testing may be appropriate. Testing cannot guarantee the prevention of side effects or improved cancer outcomes, and treatment decisions should remain under the guidance of your oncology team.
Book a Consultation